InsiderClue
Stocks · Health care · Pharmaceutical Preparations

NovaBridge Biosciences

NBP Clue Score29
United States Fiscal year ends December CIK 0001778016
$1.40 +1.82% Close, 9 Oct 2026
Alert on the numbers Alert on insider trades
Price $1.40 −97.93% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 17 Jan 2020. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
RevenueOperating incomeNet income
Fiscal year 2017Revenue11.6Net income−298.2EPS, diluted−51.93Fiscal year 2018Revenue53.8 +365.4%Net income−402.8EPS, diluted−61.70Fiscal year 2019Revenue30.0 −44.2%Net income−1,452.0EPS, diluted−201.19Fiscal year 2020Revenue1,542.7 +5,042.2%Net income470.9EPS, diluted3.00Fiscal year 2021Revenue88.0 −94.3%Net income−2,331.5 −595.1%EPS, diluted−13.35Fiscal year 2022Revenue−221.6 −351.7%Operating income−53.1Net income−2,507.3EPS, diluted−13.21Fiscal year 2023Revenue27.6Operating income−72.0Net income−1,465.7EPS, diluted−7.66Fiscal year 2024Operating income−51.4Net income−22.2EPS, diluted−0.27Fiscal year 2025Operating income−94.3Net income−88.3EPS, diluted−0.21
FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue 11.6 53.8 30.0 1,542.7 88.0 −221.6 27.6 n/a n/a
Growth +365.4% −44.2% +5,042.2% −94.3% −351.7%
Operating income n/a n/a n/a n/a n/a −53.1 −72.0 −51.4 −94.3
Net income −298.2 −402.8 −1,452.0 470.9 −2,331.5 −2,507.3 −1,465.7 −22.2 −88.3
Growth −595.1%
EPS, diluted −51.93 −61.70 −201.19 3.00 −13.35 −13.21 −7.66 −0.27 −0.21

Margins

How much of each dollar of revenue it keeps. Point at a year for the detail.
Operating marginNet margin
Fiscal year 2017Net margin−2,580.8%Free cash flow margin−2,357.9%Fiscal year 2018Net margin−749.0%Free cash flow margin−548.7%Fiscal year 2019Net margin−4,839.8%Free cash flow margin−2,934.1%Fiscal year 2020Net margin30.5%Free cash flow margin27.6%Fiscal year 2021Net margin−2,648.7%Free cash flow margin−1,139.5%Fiscal year 2022Operating margin24.0%Net margin1,131.6%Free cash flow margin518.4%Fiscal year 2023Operating margin−260.5%Net margin−5,302.0%Free cash flow margin−4,761.6%Fiscal year 2024Fiscal year 2025
FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating margin n/a n/a n/a n/a n/a 24.0% −260.5% n/a n/a
Net margin −2,580.8% −749.0% −4,839.8% 30.5% −2,648.7% 1,131.6% −5,302.0% n/a n/a
Free cash flow margin −2,357.9% −548.7% −2,934.1% 27.6% −1,139.5% 518.4% −4,761.6% n/a n/a

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flowCapital expenditureFree cash flow
Fiscal year 2017Operating cash flow−252.2Capital expenditure−20.3Free cash flow−272.5Fiscal year 2018Operating cash flow−280.7Capital expenditure−14.4Free cash flow−295.1Fiscal year 2019Operating cash flow−868.0Capital expenditure−12.2Free cash flow−880.2Fiscal year 2020Operating cash flow433.6Capital expenditure−8.0Free cash flow425.6Fiscal year 2021Operating cash flow−973.1Capital expenditure−29.9Free cash flow−1,003.0 −335.7%Fiscal year 2022Operating cash flow−1,102.8Capital expenditure−45.8Free cash flow−1,148.6Fiscal year 2023Operating cash flow−1,305.0Capital expenditure−11.4Free cash flow−1,316.3Fiscal year 2024Operating cash flow−52.7Fiscal year 2025Operating cash flow−20.6
FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow −252.2 −280.7 −868.0 433.6 −973.1 −1,102.8 −1,305.0 −52.7 −20.6
Capital expenditure −20.3 −14.4 −12.2 −8.0 −29.9 −45.8 −11.4 n/a n/a
Free cash flow −272.5 −295.1 −880.2 425.6 −1,003.0 −1,148.6 −1,316.3 n/a n/a
Growth −335.7%

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
Cash
Fiscal year 2017Shareholders’ equity−299.8Fiscal year 2018Cash241.5Shareholders’ equity−955.1Fiscal year 2019Cash163.4Shareholders’ equity−2,034.7Fiscal year 2020Cash729.3Shareholders’ equity5,627.1Fiscal year 2021Cash552.9Shareholders’ equity4,559.6Fiscal year 2022Cash342.9Shareholders’ equity2,909.9Fiscal year 2023Cash291.5Shareholders’ equity1,718.2Fiscal year 2024Cash68.3Fiscal year 2025Cash210.6
FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Cash n/a 241.5 163.4 729.3 552.9 342.9 291.5 68.3 210.6
Shareholders’ equity −299.8 −955.1 −2,034.7 5,627.1 4,559.6 2,909.9 1,718.2 n/a n/a

In millions of CNY, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Income statement

In millions of CNY, except per-share figures; shares in millions. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2017 31 Dec 2017 FY2018 31 Dec 2018 FY2019 31 Dec 2019 FY2020† 31 Dec 2020 FY2021 31 Dec 2021 FY2022 31 Dec 2022 FY2023 31 Dec 2023 FY2024 31 Dec 2024 FY2025 31 Dec 2025
Revenue and profit
11.6 53.8 30.0 1,542.7 88.0 −221.6 27.6 n/a n/a
Growth +365.4% −44.2% +5,042.2% −94.3% −351.7%
n/a n/a 0.0 0.0 46.4 27.2 n/a n/a n/a
267.1 426.0 840.4 984.7 1,213.0 904.9 810.6 n/a n/a
25.4 66.4 654.6 402.4 899.9 815.8 453.0 n/a n/a
n/a n/a n/a n/a n/a −53.1 −72.0 −51.4 −94.3
Growth
−298.2 −401.1 −1,452.0 483.1 −2,334.7 −2,506.6 −1,465.7 n/a n/a
n/a 1.7 0.0 12.2 −3.2 0.7 n/a n/a n/a
−298.2 −402.8 −1,452.0 470.9 −2,331.5 −2,507.3 −1,465.7 −22.2 −88.3
Growth −595.1%
Per share
−51.93 −61.70 −201.19 3.51 −13.35 −13.21 −7.66 −0.27 −0.21
−51.93 −61.70 −201.19 3.00 −13.35 −13.21 −7.66 −0.27 −0.21
Growth −545.0%
n/a 6.5 7.4 134.2 174.7 189.8 191.4 186.7 220.3
5.7 6.5 7.4 157.2 174.7 189.8 191.4 186.7 220.3
Growth +13.7% +13.1% +2,030.2% +11.1% +8.6% +0.9% −2.5% +18.0%

† The diluted share count jumps at 2020, so per-share figures either side of that column are not comparable. Usually a split, but the break lands on the restatement boundary rather than on the split date, because every column is that period’s latest filing.

Shown in CNY as filed; the screener converts to dollars.

Five years in brief

Worked out from the figures above, not from a press release
  • Revenue shrank 12.5% a year over five years.
  • A net loss in 8 of 9 years on file.